UPDATE: Morgan Stanley Initiates Infinity Pharmaceuticals at Overweight on Blood Cancer Drug Data
Morgan Stanley initiated Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $47.00 price target.
Morgan Stanley noted, "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety."
Infinity Pharmaceuticals closed at $35.20 on Friday.
Latest Ratings for INFI
|Jun 2016||Morgan Stanley||Downgrades||Overweight||Equal-weight|
|Jun 2016||Wells Fargo||Downgrades||Outperform||Market Perform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.